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Description: ce travail de thèse évalue de façon systématique les études sur l'association 
entre les dysfonctions thyroïdiennes infracliniques d'une part, et la maladie coronarienne et la 
mortalité d'autre part. Les hypothyroïdies infracliniques affectent environ 4-5% de la 
population adulte alors que la prévalence de l'hyperthyroïdie infraclinique est inférieure 
(environ 1 % ). L'éventuelle association entre elles pourrait justifier un dépistage systématique 
des dysfonctions thyroïdiennes infracliniques. Les précédentes études sur l'association entre 
l'hypothyroïdie infraclinique et la maladie coronarienne ont donné des résultats conflictuels. 
La parution de nouveaux articles récents basés sur de grandes cohortes prospectives nous a 
permis d'effectuer une méta-analyse basée uniquement sur des études de cohorte 
prospectives, augmentant ainsi la validité des résultats. 
Résultats: 10 des 12 études identifiées pour notre revue systématique sont basées sur des 
cohortes issues de la population générale ( « population-based » ), regroupant en tout 14 449 
participants. Ces 10 études examinent toutes le risque associé à l'hypothyroïdie infraclinique 
(avec 2134 événements coronariens et 2822 décès), alors que 5 étudient également le risque 
associé à l'hyperthyroïdie infraclinique (avec 1392 événements coronariens et 1993 décès). En 
utilisant un modèle statistique de type random-effect model, le risque relatif [RR] lié à 
l'hypothyroïdie infraclinique pour la maladie coronarienne est de 1.20 (intervalle de confiance 
[IC] de 95%, 0.97 à 1.49). Le risque diminue lorsque l'on regroupe uniquement les études de 
meilleure qualité (RR compris entre 1.02 et 1.08). Il est plus élevé parmi les participants de 
moins de 65 ans (RR, 1.51 [IC, 1.09 à 2.09] et 1.05 [IC, 0.90 à 1.22] pour les études dont 
l'âge moyen des participants est 2:: 65 ans). Le RR de la mortalité cardiovasculaire est de 1.18 
(IC, 0.98 à 1.42) et de 1.12 (IC, 0.99 à 1.26) pour la mortalité totale. En cas d'hyperthyroïdie 
infraclinique, les RR de la maladie coronarienne sont de 1.21 (IC, 0.88 à 1.68), de 1.19 (IC, 
0.81 à 1.76) pour la mortalité cardiovasculaire, et de 1.12 (IC, 0.89 à 1.42) pour la mortalité 
totale. 
Conclusions et perspectives : nos résultats montrent que les dysfonctions thyroïdiennes 
infracliniques (hypothyroïdie et hyperthyroïdie infracliniques) représentent un facteur de 
risque modifiable, bien que modéré, de la maladie coronarienne et de la mortalité. L'efficacité 
du traitement de ces dysfonctions thyroïdiennes infracliniques doit encore être prouvée du 
point de vue cardiovasculaire et de la mortalité. Il est nécessaire d'effectuer des études 
contrôlées contre placebo avec le risque cardiovasculaire et la mortalité comme critères 
d'efficacité, avant de pouvoir proposer des recommandations sur le dépistage des ces 
dysfonctions thyroïdiennes dans la population adulte. 
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Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for 
Coronary Heart Disease and Mortality 
Nicolas Ochs, MD; Reto Auer, MD; Douglas C. Bauer, MD; David Nanchen, MD; Jacobijn Gussekloo, MD, MPH; Jacques Cornuz, MD, MPH; 
and Nicolas Rodondi, MD, MAS 
Background: Data on the association between subclinical thyroid 
dysfunction and coronary heart disease (CHD) and rnortality are 
conflicting. 
Purpose: To surnrnarize prospective evidence about the relationship 
between subclinical thyroid dysfunction and CHD and rnortality. 
Data Sources: MEDLINE (1950 to January 2008) without language 
restrictions and reference lists of retrieved articles were searched. 
Study Selection: Two reviewers screened and selected cohort stud-
ies that rneasured thyroid function and then followed persans pro-
spectively to assess CHD or rnortality. 
Data Extraction: By using a standardized protocol and forrns, 2 
reviewers independently abstracted and assessed studies. 
Data Synthesis: Ten of 12 identified studies involved population-
based cohorts that included 14 449 participants. Ali 10 population-
based cohort studies exarnined risks associated with subclinical 
hypothyroidisrn (2134 CHD events and 2822 deaths), whereas only 
5 exarnined risks associated with subclinical hyperthyroidisrn (1392 
CHD events and 1993 deaths). ln a randorn-effects rnodel, the 
relative risk (RR) for subclinical hypothyroidisrn for CHD was 1.20 
ubclinical thyroid dysfunction refers to patients who have 
abnormal thyrotropin (thyroid-stimulating hormone 
[TSH]) level and a normal free thyroxine (T 4) level (1). 
The prevalence of subclinical hypothyroidism is about 
4.3% in adults (0.7% for subclinical hyperthyroidism), and 
prevalence is higher in older adu!ts and women (2-5). 
Controversy persists about whether screening and treating 
subclinical thyroid dysfonction is warranted (1, 5-7) be-
cause current evidence about the risks is limited (1, 5) and 
randomized, controlled trials on relevant clinical outcomes 
have not been clone (5, 8). 
Subclinical hypothyroidism has been associated with 
elevated cholesterol levels (9 -11) and increased risk for 
atherosclerosis (12, 13). Yet, data on the relationship be-
tween subclinical hypothyroidism and coronary heart dis-
ease (CHD) events are conflicting (12, 14-17). ln a pre-
vious meta-analysis (18), we found that subclinical 
hypothyroidism was associated with a 1.65-fold increased 
risk (CI, 1.28 to 2.12) for CHD. However, that meta-
analysis included several cross-sectional and case-contrai 
studies and only 5 small prospective studies. Recently, 3 
large prospective studies on this issue have been published 
(14, 16, 17), with somewhat inconsistent resu!ts. Because 
these new data include many additional CHD events, data 
are now sufficient to do a mera-analysis that includes only 
prospective studies, which provide greater validity. Data on 
8321 © 2008 American College of Physicians 
(95% Cl, 0.97 to 1.49; P for heterogeneity = 0.14; 12 = 33.4%). 
Risk estirnates were lower when higher-quality studies were pooled 
(RR, 1.02 to 1.08) and were higher arnong participants younger 
than 65 years (RR, 1.51 [Cl, 1.09 to 2.09] for studies with rnean 
participant age <65 years and 1.05 [Cl, 0.90 to 1.22] for studies 
with rnean participant age 2::65 years). The RR was 1.18 (Cl, 0.98 
to 1.42) for cardiovascular rnortality and 1.12 (Cl, 0.99 to 1.26) for 
total rnortality. For subclinical hyperthyroidisrn, the RR was 1.21 
(Cl, 0.88 to 1.68) for CHD, 1.19 (Cl, 0.81 to 1.76) for cardio-
vascular rnortality, and 1.12 (Cl, 0.89 to 1.42) for total rnortality (P 
for heterogeneity >0.50; 12 = 0% for all studies). 
Limitations: lndividual studies adjusted for different potential con-
founders, and 1 study provided only unadjusted data. Publication 
bias or selective reporting of outcornes could not be excluded. 
Conclusion: Subclinical hypothyroidisrn and hyperthyroidisrn rnay 
be associated with a rnodest increased risk for CHD and rnortality, 
with lower risk estirnates when pooling higher-quality studies and 
larger Cls for subclinical hyperthyroidisrn. 
Ann lntern Med. 2008;148:832-845. 
For author affiliations, see end of text. 
www.annals.org 
the association between subclinical hypothyroidism and 
mortality are also conflicting (14, 17, 19, 20). 
The consequences of subclinical hyperthyroidism have 
been Jess frequently studied than those of subclinical hypo-
thyroidism. Subclinical hyperthyroidism has been associ-
ated with cardiovascular and total mortality (15), but with 
conflicting data (14, 17). Two of the 3 recent, large pro-
spective studies (14, 17) also examined CHD and mortal-
ity in subclinical hyperthyroid participants. To summarize 
prospective evidence about the relationship between sub-
clinical thyroid dysfonction and CHD and mortality, we 
did a systematic review of prospective cohort studies. 
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Subclinical Thyroid Dysfunction and Coronary Heart Disease or Mortality REVIEW 
Context 
ls subclinical thyroid dysfunction associated with increased 
risk for coronary heart disease and mortality? 
Contribution 
This systematic review of 12 prospective cohort studies 
found that bath subclinical hypothyroidism and hyper-
thyroidism were possibly associated with a small increased 
risk for coronary heart disease and mortality. 
Caution 
Data were uncertain. Confidence intervals around risk esti-
mates were wide, particularly for those related to sub-
clinical hyperthyroidism. Higher-quality studies showed 
lower estimates of risk than lower-quality studies. 
Implication 
Randomized trials testing the efficacy of thyroxine replace-
ment and antithyroid medications for subclinical hypothy-
roidism and subclinical hyperthyroidism are needed. 
-The Editors 
METHODS 
We followed a standardized protocol and conducted 
and reported this analysis according to the guidelines of the 
Meta-analysis Of Observational Studies in Epidemiology 
group (21). 
Data Sources and Searches 
We conducted a systematic literature search of MED-
LINE for articles in any language on the association be-
tween subclinical thyroid dysfonction (bath subclinical 
hypothyroidism and hyperthyroidism) and CHD or mor-
tality (cardiovascular and total) published from 1950 to 
January 2008. To avoid missing any relevant study, we also 
searched the bibliographies of key articles in the field and 
those included in this review. We did our search on an 
Ovid (MEDLINE) server by using broadly defined Medi-
cal Subject Headings, such as thyroid diseases, hypo-
thyroidism, hyperthyroidism, thyroid hormones, thyrotropin, 
mortality, myocardial ischemia, survival, and cardiovascular 
diseases and such keywords as subclinical hypothyroidism, 
subclinical hyperthyroidism, subclinical dysthyroidism, and 
subclinical thyroid, combined with the filter designed by 
knowledge information specialists from BM] to select 
prospective studies (MEDLINE cohort-study filter) (22) 
but without their year limitation. 
Study Selection 
Two reviewers independently screened the abstracts 
and titles of the search results and eliminated articles only 
if they did not clearly study the association between sub-
clinical thyroid dysfonction and CHD or mortality (cardio-
vascular or total) in a prospective design. The same 2 re-
www.annals.org 
viewers independently evaluated the remammg foll-text 
articles for eligibility on the basis of a predefined set of 
eligibility criteria. Disagreements were resolved by consen-
sus. We included only foll-text, published, longitudinal co-
hort studies that measured thyroid fonction and followed 
persans prospectively, assessed CHD or mortality, and pro-
vided risk estimates or sufficient data to calculate risk esti-
mates associated with subclinical thyroid dysfonction 
compared with normal thyroid fonction. Subclinical hypo-
thyroidism was defined as elevated TSH levels and normal 
T 4 levels (1). Severa! reviews suggest a TSH upper limit 
cutoff of 4.5 to 5.0 mU/L (1, 5), but others suggest de-
creasing the upper limit of the TSH range to 2.5 to 3.0 
mU/L (23, 24). In the absence of consensus, we did not 
prespecify a TSH cutoff value to define subclinical hypo-
thyroidism and did a sensitivity analysis by limiting the 
analysis to studies with a TSH cutoff of 4.5 mU/L or 
greater (5). Because most adults with elevated TSH levels 
have subclinical and not overt hypothyroidism (2), we in-
cluded 2 studies with participants who had elevated TSH 
levels without a T4 measurement report (25, 26) and did a 
sensitivity analysis excluding those studies. 
For subclinical hyperthyroidism, we did not specify a 
TSH cutoff value (in the absence of consensus), but ail 
studies had a cutoff value close to 0.3 to 0.5 mU/L. We 
included 1 study with participants who had low TSH levels 
without a reported T 4 measurement (26) and did a sensi-
tivity analysis excluding this study. For CHD, we considered 
myocardial infarction, angina, the acute coronary syn-
drome, revascularization (coronary artery surgery, percuta-
neous transluminal coronary angioplasty), and significant 
coronary stenosis (defined as 250%) (27). We also consid-
ered death due to CHO or cardiovascular disease and did a 
sensitivity analysis excluding studies that only included the 
latter. We assessed methods and criteria used for adjudica-
tion of those outcomes. 
The agreement between the 2 reviewers was 99.5% for 
the first screen (rides and abstracts; K = 0.79) and 100% 
for the foll-text screen (K = 1.00). 
Data Extraction and Quality Assessment 
Two reviewers independently abstracted data on par-
ticipant characteristics, criteria used to define subclinical 
thyroid dysfonction, CHD and mortality data, and study 
results with adjustment factors by using a standardized data 
collection form. Discrepancies in data extraction between 
reviewers were resolved by consensus. We systematically 
assessed key indicators of study quality (28): methods of 
outcome adjudication and ascertainment that account for 
confounders and completeness of follow-up ascertainment. 
Similar to our previous meta-analysis (18), study popula-
tions were considered either a convenience or a population-
based sample (defined as a random sample of the general 
population) (29). Methods of outcome adjudication were 
categorized as use of formai adjudication procedures and 
adjudication without knowledge of thyroid status. A for-
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Table 1. Population-Based Studies of Subclinical Thyroid Dysfonction and Risk for CHD and Mortality* 
Study, Year (Reference) 
Subclinlcal hypothyroidlsm 
Population-based studies:J: 
Aho et al., 1984 (25) 
Vanderpump et al., 
1996 (30) (Whickham 
study) 
Hak et al., 2000 (12) 
(Rotterdam study) 
Parle et al., 2001 (15) 
lmaizumi et al., 
2004 (20) (Nagasaki 
Adult Health Study) 
Gussekloo et al., 
2004 (19) (Leiden 
85-plus Study) 
Rodondl et al., 
2005 (16) (Health, 
Aging, and Body 
Composition Study) 
Walsh et al., 2005 (17) 
(Busselton Health 
Study) 
Cappola et al., 
2006 (14) 
(Cardiovascular 
Health Study) 
Bauer et al., 2007 (26) 
(Study of 
Osteoporotic 
Fractures) 
Convenience sample 
lervasi et al., 2007 (31) 
Subclinical hyperthyroidism 
Population-based studies:J: 
Parle et al., 2001 (15) 
Sample 
280 men from rural areas of eastern and southwestern Finland 
478 adults from mixed urban and rural areas near Newcastle, 
United Kingdom** 
957 women living ln a district ln Rotterdam, the Netherlands 
1171 community-dwelling adults ln Birmingham, United 
Kingdom 
999 atomîc bomb survlvors in Nagasaki, Japan 
2550 atomic bomb survivors in Nagasaki, Japan 
999 atomic bomb survivors in Nagasaki, Japan 
558 adults living in 1 urban district in Leiden, the Netherlands 
2730 communlty-dwelling adults in areas surrounding 
Pittsburgh, Pennsylvanla, and Memphis, Tennessee 
1926 adults living in Busselton, Western Australia 
3233 community-dwelling adults in 4 U.S. communlties: 
Washington County, Maryland; Allegheny County, 
Pennsylvania; Sacramento County, Californla; and Forsyth 
County, North Carolina 
487 community-dwelling women in 4 U.S. communities: 
Portland, Oregon; Minneapolis, Minnesota; Baltimore, 
Maryland; and the Monongahela Valley, Pennsylvaniall 11 
3121 patients admitted to 1 cardiology department (Pisa, 
ltaly), excluding those with ACS or severe illness 
1171 community-dwelling adults in Birmingham, United 
Kingdom 
Mean Age Women, 
(Range or SD), y % 
64.5 (55-74)§ 0 
46 (18-95) 55.3 
69 (>55) 100 
70.4 (>60) 57.2 
58 (10) 0 
58 (10) 60.8 
58 (10) 0 
85 66 
74.7 (70-79) 51 
49.8 (17-89) 49.6 
72.7 (?:65) 59.6 
71.7 (?:65) 100 
61.1 (60.7-61.5) 32.6 
70.4 (>60) 57.2 
Follow-up 
Initial Du ration 
1974 5y 
1972-1974 20 y 
1990-1993 4.6y 
1988-1989 8.2 y 
1984-1987 6y 
1984-1987 10 y 
1984-1987 6y 
1997-1999 3.7 y 
NR 4y 
1981 20 y 
1989-1990 12.5 y 
1986-1988 11.9 y 
2000-2006 2.7y 
1988-1989 8.2 y 
mal adjudication procedure was defined as having clear 
criteria for the outcomes that were reviewed by experts for 
each potential case (29) (for example, specific electrocar-
diogram or cardiac enzyme modifications for CHD). We 
did not consider CHD adjudication based only on death 
certificates as a formai adjudication procedure. If an article 
did not clearly mention 1 of these criteria, we considered 
that it had not been done. 
We contacted the authors of 7 studies (12, 14, 15, 19, 
26, 30, 31) that met inclusion criteria but did not provide 
specific data on the assoc1at1ons between subclinical thy-
roid dysfonction and CHD or mortality. We obtained risk 
estimates and Cls for cardiovascular and total mortality 
from cohort studies in the United Kingdom (15) and the 
Netherlands (19), as well as specific data for CHD mortal-
ity from a cohort of cardiac patients in ltaly (31). Authors 
of a cohort study that published data about the relationship 
between autoimmune thyroid disease and CHD (30) pro-
vided us with data specific to subclinical hypothyroidism 
that were available for a subgroup of the participants. 
83413 June 20081 An nais of' Internai 1v1edkinc 1 Volume 148 • Number 11 www.annals.org 
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Table 1-Continued 
TSH Cutoff Value, 
mUIL (Number of 
Participants with 
Abnormal TSH 
Level) 
Based on TSH 
distribution (24)11 
>6.0 (26) 
>4.0 (107) 
>5.0 (69) 
>5.0 (96) 
>5.0 (257) 
>5.0 (96) 
>4.8 (30) 
2:4.5 (338) 
2:10.0 (44) 
>4.0 (101) 
2:10.0 (44) 
>4.5 (496) 
>5.5 (36) 
4.5-10.0 (208) 
<0.44 (76) 
Repeated TSH 
Measurement 
No 
Yes, after 20 y 
No 
Yes, yearly if 
ab normal 
TSH 
No 
No 
No 
Yes, at 3 y 
No 
No 
No 
No 
No 
No 
Yes, within 3 
moto 
exclude 
transient 
dysfunction 
Yes, yearly if 
abnormal 
TSH 
Thyroxine Exclusion of 
Measured Thyroid 
Hormone/ 
Antithyroid 
Drug 
Recipients 
NR NR/NA 
Yes NR/NA 
Yes Yes/NA 
Yes Yes/Yes 
Yes Yes/NA 
Yes Yes/NA 
Yes Y es/NA 
Yes Yes/Yes 
Yes No (only in 
an SA)/NA 
Yes NR/NR 
Yes Yes/Yes§§ 
NR NR/NR 
Yes Yes/Yes 
Yes Yes/Yes 
Three studies provided us with specific numbers of out-
comes in each thyroid group (12, 14, 26). 
We used the most adjusted risk estimates available 
(the mode! containing the greatest number of covari-
ates), unless a separate mode! further adjusted for thy-
roid antibodies, because thyroid autoimmunity has been 
hypothesized to be a mediator in the association be-
tween subclinical hypothyroidism and CHD (20). We 
did a sensitivity analysis without the studies that ad-
www.annals.org 
Outcome (Euthyroid/Subclinical Hypothyroid or 
Hyperthyroid Participants). n/n 
Cardiovascular mortality (34/4) 
Ml, angina, CHD mortality (174/12) 
Fatal and nonfatal Ml (10/4) 
Total mortality (444/25) 
Cardiovascular mortality (118/1 O) 
CHD mortality (3/2) 
Total mortality (268/42) 
Cardiovascular mortality (612) 
Total mortality (180/6) 
Cardiovascular mortality (75/2) 
CHD defined as Ml, angina, CABG, CHD 
mortality (298/36) 
Total mortality (283/41) 
Cardiovascular mortality (94/10) 
CHD defined as Ml, angina, CABG, CHD 
mortality (298/5) 
Total mortality (283/8) 
Cardiovascular mortality (94/3) 
CHD defined as Ml, angina, CHD mortalityH (229/33) 
Cardiovascular mortality (170/21) 
CHD defined as Ml, angina, CHD mortalityH (229/10) 
CHD defined as fatal and nonfatal Ml, anglna, 
CABG (883/161) 
Total mortality (1170/233) 
Cardiovascular mortality (474/101) 
Total mortality (118/12) 
Cardiovascular mortality (43/3) 
Total mortality (140/27) 
CHD mortality (48/12) 
Total mortality (444/33) 
Cardiovascular mortality (118/11) 
Relative Risk (95% Cl)t 
1.25 (0.49-3.24)'11 
1.20 (0.78-1.85)'11 
2.50 (0.70-9.10) 
0.9 (0.6-1.4)tt 
1.4 (0.7-2.6)tt 
4.8 (0.8-29.3) 
1.2 (0.8-1.6) 
2.4 (0.5-11.8) 
0.55 (0.24-1.25) 
0.47 (0.11-1.90) 
0.85 (0.58-1.26) 
1.20 (0.83-1.74) 
0.74 (0.34-1.61) 
0.96 (0.35-2.61) 
2.05 (0.90-4.68) 
2.26 (0.54-9.45) 
1.8 (1.2-2.7) 
1.5 (0.9-2.5) 
2.6 (1.3-5.3) 
1.07 (0.90-1.28) 
1.14 (0.98-1.32) 
1.16 (0.92-1.46) 
1.23 (0.55-2.74) 
0.92 (0.25-3.34) 
2.01 (1.33-3.04) 
2.58 (1.38--4.87) 
1.2 (0.9-1.8)tt 
1.6 (0.8-2.9)tt 
Continued on fo//owing page 
justed fm cholesterol because high cholesterol might be 
on the causal pathway. When risk estimates and Cis 
were not provided but raw data were available (25, 30, 
32), we calculated relative risks (RRs) and Cis by using 
the Woolf method (33-35). 
Data Synthesis and Analysis 
We first qualitatively synthesized data, paying particu-
lar attention to which definitions of subclinical thyroid 
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Table 1-Continued 
Study, Year (Reference) Sample Mean Age 
(Range or SD), y 
Women, 
% 
Follow-up 
Initial Du ration 
Gussekloo et al., 558 adults living in 1 urban district in Leiden, the Netherlands 85 66.0 1997-1999 3.7y 
2004 (19) (Leiden 
85·plus Study) 
Walsh et al., 1926 adults living in Busselton, Western Australia 49.8 (17-89) 49.6 1981 20 y 
2005 (17) 
(Busselton Health 
Study) 
Cappola et al., 3233 community-dwelling adults in 4 U.S. communities: 72.7 (2!65) 59.6 1989-1990 12.5 y 
2006 (14) Washington County, Maryland; Allegheny County, 
(Cardiovascular Pennsylvania; Sacramento County, California; and Forsyth 
Health Study) County, North Carolina 
Bauer et al., 487 community-dwelling women in 4 U.S. communities: 71.7 (2!65) 100 1986-1988 11.9 y 
2007 (26) (Study Portland, Oregon; Minneapolis, Minnesota; Baltimore, 
of Osteoporotic Maryland; and the Monongahela Valley, Pennsylvaniall 11 
Fractures) 
Convenience sample 
Radâcsi et al., 93 patients with a history of stroke or hip replacement 77 (64-87) 64.5 NR 2y 
2003 (32) undergoing rehabilitation at a geriatric hospltal in Hungary 
lervasi et al., 3121 patients admitted to 1 cardiology department (Pisa, 61.1 (60.7-61.5) 32.6 2000-2006 2.7 y 
2007 (31) ltaly), excluding those with ACS or severe illness 
* ACS = acute coronary syndrome; CABG = coronary artery bypass graft; CHO = coronary heart disease; MI = myocardial infarction; NA = not applicable; NR = not 
reported; SA = sensitivity analysis; TSH = thyroid-stimulating hormone. 
t Relative risks were estimated on the basis ofhazard ratios in 8 studies {14-17, 19, 20, 26, 31). 
:j: A population-ba.sed study was defined as a random sample of the general population. 
§ The mean age for this population was not available in the article or from the authors and was assumed to be age 64.5 years. 
Il Elevated TSH was defined as a TSH level >2 SOs above the mean of the thyroid autoantibody-negative participants. 
'Il Relative risks and Cls were calculated from raw data. 
* * Data specific to subclinical hypothyroidism, defincd as clcvated TSH lcvds, and the devclopmcnt of CHO wcre availablc from the authors only for a subgroup of the study. 
tt Study authors provided relative risk for subclinical hypothyroidism after exclusion of 18 participants with low thyroxine levels and relative risk for subclinical hyperthyroidism after 
exclusion of 2 participants with high thyroxine levels. 
:j::j: Coronary heart diseasc evcnts were dcfincd a.s dcath from CHO or hospital admission wirh a diagnosis of CHO (International Classification of Disca.ses. Ninth Revision, Clinicat 
Modification, codes 410-414). 
§§This study also accounred for thyroid hormone use during follow-up, analyûng it as a time-dependant covariate. 
1111 Nested sample of the overall cohort. 
dysfonction were used and which outcomes were mea-
sured. To calculate summary estimates and Cls of the risk 
for subclinical thyroid dysfonction, we pooled both RRs 
and hazard ratios (HRs) by using random-effects models 
based on the variance model developed by DerSimonian 
and Laird (36). Analyses were repeated by using fixed-
effects models for comparison. The presence of hetero-
geneity across studies was evaluated by using the Q statistic 
with a conserva rive P value of O. 10 (3 7), We also calculated 
the I 2 statistic, which describes the total variation across 
studies attributable to heterogeneity rather than chance; an 
12 value greater than 50% indicated at least moderate sta-
tistical heterogeneity (38). To explore sources of heteroge-
neity, we did several predefined sensitivity and subgroup 
analyses, all with a random-effects model. Given the recent 
findings of a possible protective effect of subclinical hypo-
thyroidism in very elderly persons (19, 39), we conducted 
stratified analyses by mean age of the srudied populations 
by using various cutoff values (age <65 years or 265 years, 
83613 June 20081Annals of Internai McdicinclVolume 148 • Number Il 
and age <60 years, 60 to 79.9 years, or 280 years). We 
also repeated the meta-analysis after limiting the analysis to 
multiply adjusted studies, studies with a TSH cutoff value 
of 4.5 mU/L or greater or 10.0 mU/L or greater (5), stud-
ies using formal adjudication procedures, and studies that 
excluded thyroid hormone or antithyroid drug recipients. 
Finally, we did an influence analysis to assess the effect of 
individual studies on the summary estimates (40, 41). 
We used the Egger test (42) and funnel plots to help 
assess the possibility of publication bias. We conducted all 
statistical analyses by using ST AT A software, version 9 .2 
(Stara, College Station, Texas). 
Role of the Funding Source 
The Department of Ambulatory Care and Commu-
nity Medicine and the lnstitute of Social and Preventive 
Medicine of the University of Lausanne, Lausanne, Swit-
zerland, funded this study. The funding source had no role 
in defining questions, abstracting data, synthesizing results, 
www.annals.org 
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Table 1-Continued 
TSH Cutoff Value, Repeated Thyroxine Exclusion of 
mU/L (Number of TSH Measured Thyroid 
Participants with Measurement Hormone/ 
abnormal TSH Antithyroid 
Level) Drug 
Recipients 
<0.3 (17) Yes, at 3 y Yes Yes/Yes 
<0.4 (37) No Yes NR/NR 
<0.45 (47) No Yes Yes/Yes§§ 
:'S0.5 (53) No NR NR/NR 
<0.5 (21) Yes, at 2 y Yes NR/NR 
<0.3 (98) Repeated Yes Yes/Yes 
within 3 
moto 
exclude 
transient 
dysfunction 
preparing the manuscript, or deciding to submit the manu-
script for publication. 
Study Selection 
Of the 2109 reports identified, we excluded 2077 
studies that were unrelated to the association between sub-
clinical thyroid dysfonction and CHO or mortality and 20 
after detailed evaluation. Figure 1 shows details of the 
study selection. When similar data were published twice 
(19, 62), we included the original article with the most 
definitive and extractable form (19). Twelve prospective 
studies met eligibility criteria. Ten studies were popula-
tion-based studies and included 14 449 community-living 
adults without substantive comorbid conditions. Two were 
convenience samples of patients with specific dîseases: car-
diac patients (31) or patients with a history of stroke or hip 
replacement (32). Given the clinical heterogeneity between 
these 2 types of studies, we pooled the 10 population-based 
www.annals.org 
Outcome (Euthyroid/Subclinical Hypothyroid or Relative Risk (95% 
Hyperthyroid Participants), n Cl)t 
Total mortality (18017) 1.20 (0.59-2.69) 
Cardiovascular mortality (75/3) 1.38 (0.43-4.39) 
CHD defined as Ml, angina, CHD mortality H (229/5) 1.3 (0.6--3.3) 
Cardiovascular mortality (170/3) 1.0 (0.2--4.3) 
CHD defined as fatal and nonfatal Ml, angina, 1.04 (0.64-1.69) 
CABG (883/18) 
Total mortality (1170124) 1.08 (0.72-1.62) 
Cardiovascular mortality (474/9) 0.94 (0.49-1.83) 
Total mortality (118/17) 0.86 (0.39-1.87) 
Cardiovascular mortality (43/7) 0.91 (0.28-2.95) 
Total mortality (18/10) 1.69 (0.93-3.07)~ 
Cardiovascular mortality (2/5) 7.62 (1.59-36.40)~ 
Total mortality (140/9) 1.22 (0.62-2.40) 
CHD mortality (48/7) 2.67 (1.20-5.92) 
studies as the core of this analysis and examined the addi-
tion of the 2 convenience samples in subsidiaty analyses. 
Ali 10 of the population-based studies examined subclini-
cal hypothyroidism, and 5 also examined subclinical hyper-
thyroidism. 
Description and Quality of Studies 
Table 1 shows the study characteristics and the effect 
of subclinical hypothyroidism and hyperthyroidism on the 
risk for CHO and cardiovascular and total mortality. Par-
ticipants were mostly middle-aged or older men and 
women. Follow-up ranged from 2 to 20 years. Ali studies 
used standard assays for thyroid fonction (63), with TSH 
cutoff values of 4.0 to 6.0 mU/L for subclinical hypothy-
roidism and 0.3 to 0.5 mU/L for subclinical hyperthyroid-
ism. Only the 2 convenience samples of patients were spe-
cifically designed to evaluate associations between thyroîd 
fonction and CHO or mortality (31, 32). Three studies 
repeated assessments of thyroid fonction before the end of 
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Figure 1. Study flow diagram. 
Potentially relevant 
studies identlfied 
electronlcally (n = 2107) 
Articles identified 
from reference ~ Citations excluded on the 
llsts (43, 44) (n = 2) 
-
basis of tltle and abstract 
(n = 2077) 
Studies selected for 1 
full-text revlew (n = 32) 
Excluded (n = 20) 
No specific data on subclinical 
hypothyroidism or hyperthroldism, 
deflned as an elevated or low 
TSH level (43, 45-53): 10 
No prospective data on outcomes 
f------+ (54-60): 7 
No numerlcal data on outcomes 
(44): 1 
Ali patients treated for thyroid 
dysfunctlon (61 ): 1 
Reported the same study already 
selected without addltional 
data to extract (62): 1 
Studies abstracted 
in detail (n = 12) 
t 
Population-based studies Studies with 2 convenience 
(12,14-17,19,20,25,26,30) samples of patients with 
(n = 10) specific diseases (31, 32) 
(n = 2) 
TSH = thyroid-stimulating hormone. 
the follow-up (15, 19, 31), and 7 excluded persans treated 
with thyroid hormone. 
Study quality was heterogeneous. Five studies reported 
formal adjudication procedures, and 8 adjudicated out-
comes without knowledge of thyroid status (Appendix 
Table 1, available at www.annals.org). If an article did 
not clearly mention 1 of these characteristics, we con-
sidered it not to have been done. When reported, 5% or 
fewer participants in most studies were lost to follow-
up. Only 4 studies adjusted for most cardiovascular risk 
factors, and several studies adjusted for only a few con-
founding factors. 
Subclinical Hypothyroidism and CHO 
Several studies suggested that subclinical hypothyroid-
ism was associated with a small increased risk for CHD; 
only 1 of these (17) had statistically significant findings 
(Figure 2). In a random-effects model, the summary RR of 
CHD associated with subclinical hypothyroidism was 1.20 
(CI, 0.97 to 1.49) for 2134 CHD events, with weak evi-
dence of heterogeneity (P for heterogeneity = 0.14; 12 = 
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33.4%) (Table 2). Studies that adjusted for cardiovascular 
risk factors yielded similar results. The summary RR was 
1.02 for the 5 studies that used formai adjudication proce-
dures and 1.08 for the 8 studies that adjudicated outcomes 
without knowledge of thyroid status. The 3 studies (14, 
16, 19) that met most of our quality criteria (Appendix 
Table 1, available at www.annals.org)-all conducted in 
older adults-had point estimates less than or close to 1.0 
(1.07 in the study by Cappola and colleagues [14]). In 
subgroup analysis by age, the summary RR was 1.51 for 
studies whose samples had mean age younger than 65 years 
and 1.05 for studies whose samples had a mean age 65 
years or older. Compared with the overall random-effects 
model, these subgroup analyses had lower heterogeneity (P 
for heterogeneity = 0.32 to 0.42; 12 = 0.0% to 15.4%). 
Using other age cutoff levels revealed a similar pattern. 
Excluding 2 studies that did not report T 4 measure-
ment (with the possible inclusion of some participants with 
overt hypothyroidism), those that included thyroid hor-
mone recipients, or those that included cardiovascular 
death instead of CHD as outcomes yielded similar results 
(data not shown). The RR of the pooled estimates from the 
2 studies that gave data for a TSH cutoff value of 10.0 
mU/L or higher was 1.69 (Cl, 0.64 to 4.45). Because data 
specific to subclinical hypothyroidism were available only 
for a subgroup in the study by Vanderpump and colleagues 
(30), we did a sensitivity analysis including ail participants 
that showed a pooled RR of 1.18 (CI, 0.96 to 1.46). 
Subclinical Hypothyroidism and Total and 
Cardiovascular Mortality 
Severa! studies demonstrated a pattern of increased 
risk for total or cardiovascular mortality associated with 
subclinical hypothyroidism (Figure 2). For 2822 deaths, 
the summary RR was 1.12 (CI, 0.99 to 1.26) for total 
mortality and 1.18 (CI, 0.98 to 1.42; P for heterogeneity 
>0.50 for both; 12 = 0%) for 1167 cardiovascular deaths. 
Most sensitivity analyses yielded similar results (Appendix 
Tables 2 and 3, available at www.annals.org). For cardio-
vascular mortality, pooling studies in which the mean age 
of participants was less than 65 years yielded an RR of 
1.50; the RR was 1.12 if participants were 65 years or 
older. However, this analysis should be considered with 
caution because of the small number of studies. 
Subclinical Hyperthyroidism and CHO 
Several studies demonstrated a pattern of an increased 
risk for CHD associated with subclinical hyperthyroidism 
(Figure 3), with a summary RR of 1.21 (CI, 0.88 to 1.68; 
P for heterogeneity 0.85; 1 2 = 0%) for 1392 CHD 
events. Most sensitivity analyses yielded similar results 
(Table 3), except for lower point estimates when 2 studies 
with adjustment for most cardiovascular risk factors 
(RR, 1.10) and 3 studies with formal adjudication proce-
dures (RR, 1.06) were pooled. We found no differences by 
mean age. 
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Figure 2. Forest plots for subclînical hypothyroidism. 
Study, Year (Reference) Subclinical Relative Risk Weight, 
Hypothyroid Euthyroid (95% Cl) % 
Group Group 
CHO Participants, CHO Participants, 
Coronary heart disease Events, n n Events, n n 
Aho et al., 1984 (25) 4 24 34 256 1.25 (0.49-3.24) 4.65 
Vanderpump et al., 1996 (30) 12 26 174 452 1.20 (0.78-1.85) 15.06 
Hak et al., 2000 (12) 4 107 10 850 2.50 (0.70-9.10) 2.68 
Parle et al., 2001 (15) 10 76 118 1026 1.40 (0.70-2.60) 8.49 
lmaizumi et al., 2004 (20) 2 257 3 2293 4.80 (0.80-29.30) 1.41 
Gussekloo et al., 2004 (19) 2 30 75 472 0.47 (0.11-1.90) 2.20 
Rodondi et al., 2005 (16) 36 338 298 2392 0.85 (0.58-1.26) 17.00 
Walsh et al., 2005 (17) 33 101 229 1752 r-- 1.80 (1.20-2.70) 16.19 
Cappola et al., 2006 (14) 161 496 883 2639 1.07 (0.90-1.28) 29.69 
Bauer et al., 2007 (26) 3 36 43 398 0.92 (0.25-3.34) 2.63 
Total (/2 = 33.4%; P = 0.140) 267 1491 1867 12 530 1.20 (0.97-1.49) 100.00 
0.1 0 10 
Study, Year (Reference) Subclinical Risk Lower Risk Higher Relative Risk Weight, 
Hypothyroid Euthyroid (95% Cl) % 
Group Group 
Oeaths, n Participants, Oeaths, n Participants, 
n n 
Total mortality 
Parle et al., 2001 (15) 25 76 444 1026 0.90 (0.60-1.40) 8.04 
lmaizuml et al., 2004 (20) 42 257 268 2293 1.20 (0.80-1.60) 12.01 
Gussekloo et al., 2004 (19) 6 30 180 472 0.55 (0.24-1.25) 2.12 
Rodondi et al., 2005 (16) 41 338 283 2392 1.20 (0.83-1.74) 10.53 
Cappola et al., 2006 (14) 233 496 1170 2639 1.14 (0.98-1.32) 65.06 
Sauer et al., 2007 (26) 12 36 118 398 1.23 (0.55-2.74) 2.24 
Total (12 = 0.0%; P = 0.51) 359 1233 2463 9220 1.12 (0.99-1.26) 100.00 
0.1 0 10 
Study, Year (Reference) Subclinical Risk Lower Risk Higher Relative Risk Weight, 
Hypothyroid Euthyroid (95% Cl) % 
Group Group 
CV Participants, CV Participants, 
Oeaths, n n Oeaths, n n 
Cardiovascular mortality 
Aho et al., 1984 (25) 4 24 34 256 1.25 (0.49-3.24) 3.84 
Parle et al., 2001 (15) 10 76 118 1026 1.40 (0.70-2 .60) 7.96 
lmaizumi et al., 2004 (20) 2 257 6 2293 2.40 (0.50-11.80) 1.37 
Gussekloo et al., 2004 (19) 2 30 75 472 0.47 (0.11-1.90) 1.69 
Rodondi et al., 2005 (16) 10 338 94 2392 0.74 (0.34-1.61) 5.67 
Walsh et al., 2005 (17) 21 101 170 1752 1.50 (0.90-2.50) 13.14 
Cappola et al., 2006 (14) 101 496 474 2639 1.16 (0.92-1.46) 64.29 
Bauer et al., 2007 (26) 3 36 43 398 0.92 (0.25-3.34) 2.04 
Total (12 = 0.0%; P = 0.65) 153 1358 1014 11 228 1.18 (0.98-1.42) 100.00 
0.1 0 10 
Risk Lower Risk Higher 
The diamonds represent relative risks and the horizontal lines represent 95% Cls of the effect of subclinical hypothyroidism. CHD = coronary heart 
disease; CV = cardiovascular. 
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Subclinical Hyperthyroidism and Total and 
Cardiovascular Mortality 
The RR for total mortality was 1.12 (CI, 0.89 to 1.42) 
for 1993 deaths and 1.19 (CI, 0.81 to 1. 76) for 913 
cardiovascular deaths (P for heterogeneity >0.80 for 
both; 1 2 = 0%) (Figure 3). Most sensitivity analysis 
yielded similar results (Appendix Tables 4 and 5, avail-
able at www.annals.org), except for an RR of 0.95 for 
cardiovascular mortality (when 2 studies adjusted for 
most cardiovascular risk factors were pooled) and 1. 01 
for 3 studies with formai adjudication procedures. 
Additional Studies Not lncluded in the Primary Analyses 
For both subclinical hypothyroidism and hyper-
thyroidism, addition of the convenience samples of pa-
tients with specific diseases (31, 32) increased the point 
estimates for CHO and mortality (summary RRs, 1.18 to 
1.55 [Tables 2 and 3; Appendix Tables 2, 3, 4, and 5, 
available at www.annals.org]). These summary RRs 
reached or were close to statistical significance but had 
increased statistical heterogeneity for ail associations. 
Publication Bias Evaluation 
We found no evidence of publication bias, either with 
visual assessment of funnel plots (data not shown) or with 
the Egger test (P >0.30 for ail associations). Because small 
negative studies are most subject to publication bias and 
some might be missing, we excluded studies with fewer 
than 500 participants and obtained similar estimates for ail 
associations. Influence analysis indicated that the exclusion 
of single studies did not substantially alter any estimates 
(data not shown). 
DISCUSSION 
In the meta-analysis of 10 population-based prospec-
tive cohort studies, we found that subclinical thyroid dys-
fonction was associated with a pattern of modest increased 
risk for CHO and mortality (summary RRs, 1.12 to 1.21). 
Estimates about subclinical hyperthyroidism, which were 
derived from only 5 studies, had wider Cis than estimates 
for subclinical hypothyroidism. In general, we found lower 
risk estimates (RR, 1.01 to 1.21), when we pooled higher-
quality studies, such as those that used formai adjudication 
procedures for outcomes although the upper bound of the 
Cls for these estimates was still consistent with overall 
summary RRs of increased risk. The relationship between 
subclinical hypothyroidism and CHO seemed to differ 
among studies that involved middle-aged versus elderly 
participants, with studies whose samples had a mean age 
younger than 65 years showing increased risk for CHO. 
Subclinical hypothyroid participants with a TSH 10.0 
mU/L or greater might also have an increased CHO risk, 
but only 2 studies reported such stratified data. Risk esti-
mates were higher when the 2 convenience samples of pa-
tients with specific diseases were added. 
For the association between subclinical hypothyroid-
Table 2. Stratified Analysis of the Association of Subclinical Hypothyroldism wlth Risk for CHO* 
Characteristic 
Eligible study model 
Random effects 
Fixed effects 
Study quality 
Formai CHD or cardiovascular mortality rate adjudication procedures 
Adjudication without knowledge of thyroid status 
Stratified by mean age 
<65 y 
265 y 
<60 y 
60-79.9 y 
280 y 
Adjustments 
Adjusted analyses or matching 
Adjusted for cardiovascular risk factors 
Definition of subclinical hypothyroidism 
TSH level 24.5 mU/L 
TSH level 210.0 mU/L 
Particular population: elderly participants excluded (19) 
Subsldlary analysls: addition of a convenlence sample of cardlac patients (31) 
* CHO = coronary heart disease; TSH = thyroid-stimulating hormone. 
t Relative risk from meta-analysis using random-effects mode!. 
Summary Relative Risk 
(95% Cl)t 
1.20 (0.97-1.49) 
1.14 (1.00-1.30) 
1.02 (0.86-1.22) 
1.08 (0.90-1.31) 
1.51 (1.09-2.09) 
1.05 (0.90-1.22) 
1.58 (1.02-2.43) 
1.06 (0.91-1.24) 
0.47 (0.11-1.90) 
1.21 (0.93-1.58) 
1.22 (0.86-1.73) 
1.06 (0.91-1.25) 
1.69 (0.64-4.45) 
1.22 (0.99-1.52) 
1.31 (1.02-1.67):f: 
:j: Addition of the convenience sample of cardiac patients increased overall statistical heterogeneiry (P for heterogeneiry = 0.03; J2 = 49.0%). 
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Figure 3. Forest plots for subclinical hyperthyroidism. 
Study, Year (Reference) Subclinical Relative Risk Weight, 
Hyperthyroid Euthyroid (95% Cl) % 
Group Group 
CHO Participants, CHO Participants, 
Coronary heart disease 
Events, n n Events, n n 
Parle et al., 2001 (15) 11 69 118 1026 1.60 (0.80-2.90) 25.41 
Gussekloo et al., 2004 (19) 3 17 75 472 1.38 (0.43-4.39) 7.81 
Walsh et al., 2005 (17) 5 37 229 1752 1.30 (0.60-3.30) 14.50 
Cappola et al., 2006 (14) 18 47 883 2639 1.04 (0.64-1.69) 44.69 
Bauer et al., 2007 (26) 7 53 43 398 0.91 (0.28-2.95) 7.60 
Total (/2 = 0.0%; P = 0.85) 44 223 1348 6287 1.21 (0.88-1.68) 100.00 
0.1 0 10 
Study, Year (Reference) Subclinical Risk Lower Risk Higher Relative Risk Weight, 
Hyperthyroid Euthyroid (95% Cl) % 
Group Group 
Oeaths, n Participants, Oeaths, n Participants, 
n n 
Total mortality 
Parle et al., 2001 (15) 33 69 444 1026 1.20 (0.90-1.80) 46.84 
Gussekloo et al., 2004 (19) 7 17 180 472 1.20 (0.59-2.69) 9.78 
Cappola et al., 2006 (14) 24 47 1170 2639 1.08 (0.72-1.62) 34.22 
Bauer et al., 2007 (26) 17 53 118 398 0.86 (0.39-1.87) 9.16 
Total (12 = 0.0%; P = 0.85) 81 186 1912 4535 1.12 (0.89-1.42) 100.00 
0.1 0 10 
Risk Lower Risk Higher 
Study, Year (Reference) Subclinical Relative Risk Weight, 
Hyperthyroid Euthyroid (95% Cl) % 
Group Group 
CV Participants, CV Participants, 
Oeaths, n n Oeaths, n n 
Cardiovascular mortality 
Parle et al., 2001 (15) 11 69 118 1026 1.60 (0.80-2.90) 36.53 
Gussekloo et al., 2004 (19) 3 17 75 472 1.38 (0.43-4.39) 11.22 
Walsh et al., 2005 (17) 3 37 170 1752 1.00 (0.20-4.30) 6.44 
Cappola et al., 2006 (14) 9 47 474 2639 0.94 (0.49-1.83) 34.89 
Bauer et al., 2007 (26) 7 53 43 398 0.91 (0.28-2.95) 10.93 
Total (12 = 0.0%; P = 0.81 ) 33 223 880 6287 1.19 (0.81-1.76) 100.00 
0.1 0 10 
Risk Lower Risk Higher 
The diamonds represent relative risks and the horizontal lines represent 95% Cis of the effect of subclinical hyperthyroidism. CHD = coronary heart 
disease; CV = cardiovascular. 
ism and CHD, several population-based studies yielded 
conflicting results. Two individual prospective studies 
found a statistically significant association between subclin-
ical hypothyroidism and CHD: the Busselton Health 
Study (HR, 1.8) (17) and a sample of cardiac patients 
(HR, 2.58) (31). However, 2 large prospective cohort stud-
ies of older adults found no increased risk for CHD (14, 
16). These 2 studies adjusted their results for most cardio-
vascular risk factors and met most of our quality criteria, 
whereas the 2 studies with substantial associations (17, 31) 
did not formally adjudicate cardiovascular outcomes or re-
www.annals.org 
port whether adjudication was done without knowledge of 
thyroid status. A meta-analysis pooled only 3 recent studies 
(14, 16, 17) and obtained a summary RR of 1.19 (Cl, 1.02 
to 1.38) (64), driven in part by the use of the unadjusted 
RR of 2.5 from the Busselton Health Study (adjusted HR, 
1.8) (65). In our previous meta-analysis (18), we found a 
statistically significant association between subclinical 
hypothyroidism and CHD (summary odds ratio, 1.65 [CI, 
1.28 to 2.12]), but that analysis included 3 case-control 
and 6 cross-sectional studies. When our previous meta-
analysis of subclinical hypothyroidism and CHD was lim-
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Table 3. Stratified Analysis of the Association of Subclinlcal Hyperthyroidism with Risk for CHO* 
Characteristic 
Eligible study models 
Random effects 
Fixed effects 
Study quality 
Formai CHD or cardiovascular mortality rate adjudication procedures 
Adjudication without knowledge of thyroid status 
Stratified by mean age 
<65 y 
;o,65 y 
<60y 
60-79.9 y 
;,,,so Y 
Adjustments 
Adjusted analyses or matching 
Adjusted for cardiovascular risk factors 
Particular population: elderly participants excluded (19) 
Subsldiary analysis: addition of 2 convenience samples (31, 32) 
* CHO = coronary heart disease. 
t Relative risk from meta-analysis using random-effects mode!. 
Summary Relative Risk Studies, 
(95% Cl)t n 
1.21 (0.88-1.68) 5 
1.21 (0.88-1.68) 5 
1.06 (0.70-1.61) 3 
1.20 (0.84-1.70) 4 
1.3 (0.6-3.3) 
1.20 (0.84-1.70) 4 
1.3 (0.6-3.3) 1 
1.18 (0.82-1.71) 3 
1.38 (0.43-4.39) 1 
1.21 (0.88-1.68) 5 
1.10 (0.72-1.68) 2 
1.20 (0.86-1.68) 4 
1.54 (1.04-2.28):t: 7 
:j: Addition of the 2 convenience samples increased overall statistical heterogeneity (P for heterogeneity = 0.17; f 2 = 34.2%). 
ited to the 5 older prospective cohort studies (12, 15, 20, 
25, 30) that were of lower quality than the more recent 
ones, the summary RR was 1.42 (CI, 0.91 to 2.21). 
Our analyses showed a pattern of higher mortality 
rates in participants with subclinical hypothyroidism, con-
sistent with 2 previous meta-analyses that found slightly 
higher risks (summary RRs, 1.25 and 1.21 [66] and 1.12 
and 1.28 [64] for total and cardiovascular mortaliry, re-
spectively). However, these older meta-analyses included 
only 4 studies with mortality outcomes (14, 16, 17, 20) 
and had some limitations, such as data extraction errors 
(64, 65) and lack of assessment of statistical heterogeneity 
or sensitiviry analyses (66). Our results might not apply to 
ail ages, because 1 study found an even lower risk for total 
mortaliry (HR, 0.55) in adults age 85 years with subclinical 
hypothyroidism than in euthyroid participants (19). 
Similar to a previous meta-analysis ( 66), we found a 
pattern of modestly increased risk for CHO and mortaliry 
associated with subclinical hyperthyroidism, with wider 
Cis than those for subclinical hypothyroidism, given the 
more limited data, and lower risk estimates when higher-
qualiry studies were pooled. Further large studies are 
needed to better assess these risks. The higher risks found 
in the 2 convenience samples of patients with specific dis-
eases, particularly for subclinical hyperthyroidism, increase 
the likelihood that subclinical thyroid dysfunction associ-
ated with other diseases might be a different, potentially 
more harmful entity than subclinical thyroid dysfunction 
among healthier individuals or that sick patients might be 
less tolerant to abnormal levels of TSH. We previously 
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found that assoc1at10ns between subclinical hypothyroid-
ism and heart failure were stronger for recurrent than for 
incident events (16). However, these differences are based 
on only 2 prospective cohorts of patients with specific dis-
eases and should be confirmed in other studies. 
We found weak evidence for statistical heterogeneiry 
among individual study findings, and age explained part of 
the heterogeneity for the association between subclinical 
hypothyroidism and CHO, with an increased risk for 
CHO only in cohorts with a younger mean age. These 
potential age differences should be interpreted with cau-
tion, given the possibiliry of ecological fallacy without in-
dividual patient data (28). One cross-sectional study did 
subgroup analyses by age and found that the risk for CHO 
associated with subclinical hypothyroidism was higher in 
younger participants (67); however, no prospective study 
presented stratified analyses by age. Although this finding 
should be confirmed by stratified analyses in future pro-
spective cohort studies with a wide age range, potential 
explanations for these age differences might be competing 
mortaliry among older adults (for example, due to cancer) 
or more competing risk factors for CHO among older 
adults (for example, age or sex). If the risk for CHO with 
subclinical hypothyroidism was mainly mediated by in-
creased cholesterol levels, it might weaken with age because 
levels of total and low-density lipoprotein cholesterol are 
strong cardiovascular risk factors in middle-age but not 
aider adults (68). Other potential explanations could be 
related to thyroid physiology in older adults (decreased 
thyroid hormone action at the tissue level, decreased thy-
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roid hormone metabolism) (39). High TSH levels in el-
derly persons might also be a compensatory mechanism for 
other perturbations, whereas in younger adults it is caused 
by thyroid dysfonction. 
Our study has several limitations. First, a meta-analysis 
of observational studies should be interpreted with caution 
(69), even though it can provide usefol information when 
only data from observational studies are available (21). To 
our knowledge, no randomized, controlled trial has studied 
the benefits of treating adults with subclinical thyroid dys-
fonction with regard to CHO or mortality (5,8). We 
found only weak evidence for statistical heterogeneity 
among studies, but some clinical heterogeneity with 
slightly different TSH cutoff levels (4.0 to 6.0 mU/L for 
subclinical hypothyroidism and 0.3 to 0.5 mU/L for sub-
clinical hyperthyroidism), varying CHO definitions, or dif-
ferent confounding factors included for adjustment. We 
could not assess the risk for specific CHO outcomes, such 
as MI or "hard" CHO (MI, coronary death) outcomes, 
because such subgroup analysis was lacking in most origi-
nal studies. However, sensitivity analyses pooling more ho-
mogeneous studies yielded similar risk estimates, although 
such estimates were lower when higher-quality studies were 
pooled. Alternative explanations for observed results are 
bias in the selection of included studies, bias and quality 
problems in the original studies, publication bias, hetero-
geneity, and confounding (21). 
To limit bias in the selection of included studies, we 
used broad inclusion criteria for studies that provided 
quantitative data on the risk for CHD or mortality as-
sociated with subclinical thyroid dysfonction and then 
did sensitivity analyses according to differences between 
the studies and methodological study quality, as recom-
mended (21, 70). We could not exclude ail participants 
with inadequately treated overt thyroid dysfonction or 
nonthyroidal illness (71) because these subgroup data 
were lacking in the original studies. Subgroup analyses 
should be interpreted with caution given the limited 
number of studies. Although our graphical and statisti-
cal analyses showed that publication bias was unlikely, it 
cannot be excluded because the capacity to detect pub-
lication bias is reduced when meta-analyses are based on 
a limited number of studies (42, 72). Selective reporting 
of the outcomes in the cohorts cannot be excluded, 
either. 
In summary, our data suggest that subclinical thyroid 
dysfonction might represent a potentially modifiable-
albeit modest-risk factor for CHO and mortality. Assum-
ing that treatment is effective, given the high prevalence of 
thyroid disease even a small increase in CHO or mortality 
rates among persans with subclinical dysfonction (such as 
the 10% to 20% increased RR in our study) would have 
public health implications. From a health policy perspec-
tive, it would be premature to recommend screening for 
thyroid dysfonction in the general population. Given the 
pattern of modestly increased risk for CHO and mortality 
www.annals.org 
associated with subclinical thyroid dysfonction, lower risk 
estimates in higher-quality studies, and the remaining un-
certainty, treatment of subclinical thyroid dysfonction with 
CHD as an end point should be studied in randomized, 
placebo-controlled trials to assess the efficacy ofT 4 replace-
ment or antithyroid medications before current recom-
mendations are updated (1, 5). 
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Appendix Table 2. Stratified Analysis of the Association of Subclinical Hypothyroidism with Risk for Total Mortality* 
Characteristic 
Eligible study model 
Random effects 
Fixed effects 
Study quality 
<5% of participants lost to follow-up:f: 
Stratified by mean age§ 
<65 y 
;o,,65 y 
<60 y 
60-79.9 y 
;o,,80 y 
Adjustments 
Adjusted analyses or matching 
Adjusted for cardiovascular risk factors 
Definltion of subclinical hypothyroidism 
TSH level ;;,45 mU/L 
TSH level ;o,;1Q.O mU/L 
Particular population: elderly participants excluded (19) 
Subsidiary analysis: addition of a convenience sample of cardiac 
patients (31) 
* TSH = thyroid-stimulating hormone. 
t Relative risk from meta-analysis using random-effects mode!. 
Summary Relative Risk 
(95% Cl)t 
1.12 (0.99-1.26) 
1.12 (0.99-1.26) 
1.13 (0.99-1.28) 
1.20 (0.80-1.60) 
1.10 (0.96-1.26) 
1.20 (0.80-1.60) 
1.12 (0.99-1.28) 
0.55 (0.24-1.25) 
1.12 (0.99-1.26) 
1.15 (1.00-1.32) 
1.12 (0.99-1.26) 
2.05 (0.90-4.68) 
1.13 (1.00-1.28) 
1.18 (0.96-1.44)11 
:j: A cutoff of <5% of participants lost to follow-up was considered appropriate on the basis of retention data of other large cohort studies (73). 
§ The number of studies in each age category is small, with only 1 study in the younger age groups. 
Il Addition of the convenience sample of cardiac patients increased overall statistical heterogeneity (P for heterogeneity = 0.08; 12 = 47.6%). 
Studies, 
n 
6 
6 
4 
1 
5 
1 
4 
1 
6 
2 
6 
5 
7 
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Appendix Table 3. Stratified Analysis of the Association of Subclinical Hypothyroldism wlth Risk for Cardiovascular Mortality* 
Characteristic 
Eligible study model 
Random effects 
Fixed effects 
Study quality 
Formai cardiovascular mortality rate adjudication procedures 
Adjudication without knowledge of thyroid status 
Stratified by mean age 
<65 y 
265 y 
<60 y 
60-79.9 y 
280 y 
Adjustments 
Adjusted analyses or matching 
Adjusted for cardiovascular risk factors 
Definltion of subclinical hypothyroidism 
TSH level 24.5 mU/L 
TSH level 210.0 mU/L 
Particular population: elderly participants excluded (19) 
Subsidlary analysls: addition of a convenience sample of cardiac patients (31) 
* TSH = thyroid-stimulating hormone. 
t Relative risk from meta-analysis by using random-effects model. 
Summary Relative Risk 
(95% Cl)t 
1.18 (0.98-1.42) 
1.18 (0.98-1.42) 
1.09 (0.88-1.35) 
1.13 (0.92-1.39) 
1.50 (0.97-2.30) 
1.12 (0.91-1.37) 
1.57 (0.96-2.55) 
1.14 (0.93-1.40) 
0.47 (0.11-1.90) 
1.18 (0.98-1.42) 
1.17 (0.92-1.49) 
1.13 (0.92-1.39) 
2.26 (0.54-9.45) 
1.20 (0.99-1.44) 
1.29 (1.01-1.67):f: 
:f: Addition of the convenience sample of cardiac patients increased overall statistical heterogeneity (P for heterogeneity = 0.24; 12 = 23.4%). 
Appendix Table 4, Stratified Analysis of the Association of Subclinical Hyperthyroldism with Risk for Total Mortality* 
Characteristics 
Eligible study model 
Random effects 
Fixed effects 
Study quality 
<5% of participants lost to follow-upt 
Adjustments 
Adjusted analyses or matching 
Adjusted for cardiovascular risk factors 
Particular population: elderly participants excluded (19) 
Subsldlary analysls: addition of 2 convenlence samples (31, 32) 
Summary Relative Risk 
(95% Cl)t 
1.12 (0.89-1.42) 
1.12 (0.89-1.42) 
1.12 (0.87-1.43) 
1.12 (0.89-1.42) 
1.08 (0.72-1.62) 
1.12 (0.87-1.43) 
1.19 (0.97-1.47)§ 
* Stratified analyses by mean age are not reported for this relationship because of the limited number of studies. 
t Relative risk from meta-analysis using random-effects model. 
:f: A cutoff of <5% of participants lost to follow-up was considered appropriate on the basis of retention data of other large cohort studies (73). 
§Addition of the 2 convenience samples did not increase overall statistical heterogeneity (P for heterogeneity = 0.82; 12 = 0%). 
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Studies, 
n 
8 
8 
4 
6 
3 
5 
2 
5 
8 
3 
6 
1 
7 
9 
Studies, 
n 
4 
4 
3 
4 
1 
3 
6 
www.annals.org 
Appendix Table 5. Stratified Analysis of the Association of Subclinical Hyperthyroldism with Risk for Cardiovascular Mortality* 
Characteristics 
Eligible study model 
Random effects 
Fixed effects 
Study quality 
Formai cardiovascular mortality rate adjudication procedures 
Adjudication without knowledge of thyroid status 
Adjustments 
Adjusted analyses or matching 
Adjusted for cardiovascular risk factors 
Particular population: elderly participants excluded (19) 
Subsidiary analysis: addition of 2 convenience samples (31, 32) 
Summary Relative Risk 
(95% Cl)t 
1.19 (0.81-1.76) 
1.19 (0.81-1.76) 
1.01 (0.60-1.69) 
1.21 (0.81-1.81) 
1.19 (0.81-1.76) 
0.95 (0.52-1.74) 
1.17 (0.77-1.77) 
1.55 (0.99-2.43):1: 
* Stratified analyses by mean age are not reported for this relationship because of the limited number of studies. 
t Relative risk from meta-analysis using random-efîects mode!. 
:j: Addition of the 2 convenience samples increased overall statistical heterogeneity (P for heterogeneity = 0.17; / 2 = 34.0%). 
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Appendiv: Table 1. Quality Assessment of lncluded Studies* 
Study, Year (Reference) 
Population-based studies 
Aho et al., 1984 (25) 
Vanderpump et al., 1996 (30) (Whickham 
study) 
Hak et al., 2000 (12) (Rotterdam study) 
Parle et al., 2001 (15) 
lmaizumi et al., 2004 (20) (Nagasaki Adult 
Health Study) 
Gussekloo et al., 2004 (19) (Leiden 85-plus 
Study) 
Rodondi et al., 2005 (16) (Health, Aging, and 
Body Composition Study) 
Walsh et al., 2005 (17) (Busselton Health 
Study) 
Cappola et al., 2006 (14) (Cardiovascular 
Health Study) 
Bauer et al., 2007 (26) (Study of Osteoporotic 
Fractures) 
Convenience samples 
Radâcsi et al., 2003 (32) 
lervasi et al., 2007 (31) 
Formai 
Adjudication 
Procedures for 
CH Dt 
NA 
No 
Yes 
NA 
NA 
NA 
Yes 
No 
Yes 
NA 
NA 
NA 
Methods for CHO Ascertainment 
NA 
Self-reported history of angina or Ml confirmed by general 
practitioners or hospital records 
Reports from general practitioners and hospital records 
NA 
NA 
NA 
Interview, hospital records, and other support documents 
reviewed by a panel of clinicians 
Hospital records: diagnoses coded with ICD-9 and ICD-10 
Interview, hospital records reviewed by experts 
NA 
NA 
NA 
Formai Methods for Cardiovascular Mortality Rate Ascertainment 
Adjudication 
Procedures 
for 
Cardiovascular 
Mortality 
Ratet 
No NR 
NA Death certificates, postmortem reports, hospital or general practitioners' reports, 
ECG during the final illness coded (36%) 
NA NA 
No Death certificates; causes of death coded with ICD-9 
No Death certificates; causes of death coded with ICD-9 
Yes Mortality information from general practitioners with a standardized 
questionnaire: causes of death coded by 2 experts with ICD-10 
Yes Hospital records, death certificates, and other support documents reviewed by a 
panel of clinicians 
No Registrar General's lis! of deaths: coded with ICD-9 and ICD-10 
Yes Medical records, death certificates, autopsy reports, and coroners' reports 
reviewed by experts 
Yes Hospital records, death certificates reviewed by a physician-investigator and 
coded with ICD-9 
No Death information obtained from general practitioners 
No Death certificates, hospital records, general practitioner and patient interviews 
(if living) 
Adjudication 
without 
Knowledge 
of Thyroid 
Status 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
Lost to 
Follow-up, % 
NR 
3 
1.8 
0.1 
O for mortality 
12.5 
NR 
5 
O for mortality 
NR 
o for mortality 
Adjustments 
Age- and locality-matched, unadjusted 
Unadjusted 
Age, BMI, total cholesterol, HDL, BP, 
and smoking 
Age and sex 
Age, sex, and smoking 
Sex and education 
Age, sex, race, smoking, diabetes, 
prevalent CVD, poor or fair health, 
BP, total cholesterol, creatinine, 
education, incarne, thyroid 
hormone, and ACE inhibitor use 
Age, sex, BMI, smoking, diabetes, 
total cholesterol, triglycerides, BP, 
hypertensive therapy, exercise, and 
thyroid disease 
Age, sex, prevalent CVD, thyroid 
medication, race, smoking, diabetes, 
LDL cholesterol, lipid-lowering 
drugs, hypertension, BMI, and CRP 
Age, weight, thyroid hormone or 
estrogen use, history of 
hyperthyroidism 
Unadjusted 
Age, sex, ischemic and nonischemic 
heart disease 
Report of Missing Covariates 
NR 
NR 
BMI, 8; BP, 5; HDL, 4; smoking: 18 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
• If an article did not clearly mention 1 of these characteristics, we considered it not ta have been done. ACE = angiotensin-converting enzyme; BMI = body mass index; BP blood pressure; CHD = coronary heart disease; CRI' = C-reactive protein; CVD = cardiovascular disease; ECG = electrocardiography; HDL = high-density lipoprotein; !CD =International 
Classification of Diseases; LDL = low-density lipoprotein; MI = myocardial infarction; NA = not applicable (because the outcome was not examined in the study); NR = not reported. 
t A formai adjudication procedure was defined as having clear criteria for the outcome that were reviewed by experts for each potential case. 
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